Clinical and Genomic Profiles of Korean Patients with MECOM Rearrangement and the t(3;21)(q26.2;q22.1) Translocation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The translocation (3;21)(q26.2;q22.1) is a unique cytogenetic aberration that characterizes acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in patients with AML and myelodysplastic syndrome (MDS) or a therapy-related myeloid neoplasm. Using multigene target sequencing and FISH, we investigated the clinical and genomic profiles of patients with t(3;21) over the past 10 years. The frequency of t(3;21) among myeloid malignancies was very low (0.2%). Half of the patients had a history of cancer treatment and the remaining patients had de novo MDS. Twenty-one somatic variants were detected in patients with t(3;21), including in CBL, GATA2, and SF3B1. Recurrent variants in RUNX1 (c.1184A>C, p.Glu395Ala) at the same site were detected in two patients. None of the patients with t(3;21) harbored germline predisposition mutations for myeloid neoplasms. MECOM rearrangement was detected at a higher rate using FISH than using G-banding, suggesting that FISH is preferable for monitoring. Although survival of patients with t(3;21) is reportedly poor, the survival of patients with t(3;21) in this study was not poor when compared with that of other AML patients in Korea.
Abstract
The translocation (3;21)(q26.2;q22.1) is a unique cytogenetic aberration that characterizes acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in patients with AML and myelodysplastic syndrome (MDS) or a therapy-related myeloid neoplasm. Using multigene target sequencing and FISH, we investigated the clinical and genomic profiles of patients with t(3;21) over the past 10 years. The frequency of t(3;21) among myeloid malignancies was very low (0.2%). Half of the patients had a history of cancer treatment and the remaining patients had de novo MDS. Twenty-one somatic variants were detected in patients with t(3;21), including in CBL, GATA2, and SF3B1. Recurrent variants in RUNX1 (c.1184A>C, p.Glu395Ala) at the same site were detected in two patients. None of the patients with t(3;21) harbored germline predisposition mutations for myeloid neoplasms. MECOM rearrangement was detected at a higher rate using FISH than using G-banding, suggesting that FISH is preferable for monitoring. Although survival of patients with t(3;21) is reportedly poor, the survival of patients with t(3;21) in this study was not poor when compared with that of other AML patients in Korea.
참고문헌 (13)
- Arber DA, "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia", Blood, 127, pp.2391~2405 (2016)
- Bejar R, "Clinical and genetic predictors of prognosis in myelodysplastic syndromes", Haematologica, 99, pp.956~964 (2014)
- Glass C, "The role of EVI1 in myeloid malignancies", Blood Cells Mol Dis, 53, pp.67~76 (2014)
- De Braekeleer M, "3q26", EVI1 rearrangements in myeloid hemopathies : a cytogenetic review, 2015, pp.11, 1675~1686
- Barbui T, "The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms : document summary and in-depth discussion", Blood Cancer J, 8, pp.15~ (2018)
- Summerer I, "Prognosis of MECOM(EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count", Leuk Lymphoma, 61, pp.1756~1759 (2020)
- Kwon J, "Differences in diagnosis, treatment, and survival rate of acute myeloid leukemia with or without disabilities: A national cohort study in the Republic of Korea", Cancer Med, 9, pp.5335~5344 (2020)
- Lee JH, "A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome", Haematologica, 96, pp.1441~1447 (2011)
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Li MM, "Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists", J Mol Diagn, 19, pp.4~23 (2017)
- Bejar R, "Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R : analysis of combined datasets from the International Working Group for Prognosis in MDS-Molecular Committee", Blood, 126, pp.907~ (2015)
- Ripperger T, "MDS1 and EVI1 complex locus(MECOM) : a novel candidate gene for hereditary hematological malignancies", Haematologica, 103, pp.e55~e58 (2018)
- Lee S, "Korean Variant Archive(KOVA) : a reference database of genetic variations in the Korean population", Sci Rep, 7, pp.4287~ (2017)